AGA Family of Websites:
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
December 2, 2019

What do 5-ASAs, biologics and immunomodulators have in common?

Complete this IBD course to find out.
Share on facebook
Share on twitter
Share on linkedin
Share on email

While aminosalicylates (5-ASAs), biologic therapies and immunomodulator medications are widely used for the treatment of inflammatory bowel disease (IBD), few clinicians have a comprehensive understanding of the pharmacologic underpinnings that make these treatments so effective.

Available on-demand through AGA University, Advanced Practice Provider Pharmacology: IBD is a two-hour course for clinicians of all background levels that presents complex technical information in five easy-to-understand modules.

Course faculty includes: Kimberly Kearns, MS, APRN, ANP-BC (Chair); Erin Darguzas, MSN, APN; and Shawna Sullivan, MSN, APRN, ACNP-BC.

Complete this course by July 31, 2020 and receive 2 AMA PRA Category 1 Credits™ or 2 AANP pharmacology contact hours.


This program is made possible by support from Gilead Sciences, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.